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Abstract
Objectives This study evaluated the waiting list for
elective electrical cardioversion (ECV) for persistent
atrial fibrillation (AF), focusing on when and why
procedures were postponed. We compared the effects
of management of the waiting list conducted by
physicians versus management by nurse practitioners
(NPs) and we evaluated the safety of our anticoagulat-
ing policy by means of bleeding or thromboembolic
complications during and after ECV.
Background Not all patients selected for ECV receive their
treatment at the first planned instance due to a variety of
reasons. These reasons are still undocumented.
Methods We evaluated 250 consecutive patients with
persistent AF admitted to our clinic for elective ECV.
Results Within 5 to 6 weeks, 186 of 242 patients (77%)
received ECV. The main reason for postponing an ECV was
an inadequate international normalised ratio (INR); other
reasons included spontaneous sinus rhythm and switch to
rate control. A total of 23 of the 147 patients (16%)
managed by the research physician were postponed due to
an inadequate INR at admission versus 4 out of 98 patients
(4%) managed by NPs (p=0.005)
Conclusion An inadequate INR is the main reason for
postponing an ECV. Management of ECV by NPs is safe
and leads to less postponing on admission.
Keywords Electrical cardioversion.INR monitoring.
Nurse practitioner
Introduction
Atrial fibrillation (AF) is the most common arrhythmia in
clinical practice. Rhythm and rate control are the two
treatment strategies of patients with AF. For most cardiol-
ogists rhythm control is the treatment of choice in
symptomatic AF patients [1, 2].
An electrical cardioversion (ECV) is one of the
therapies for rhythm control in patients with persistent
AF. Because of thromboembolic complications, an ECV
procedure has to be performed within 48 h after onset
of AF or electively after a minimum period of three
weeks of adequate level of anticoagulation [3]. For
determining adequate anticoagulation status, the interna-
tional normalised ratio (INR) can be used in patients
treated with vitamin K antagonists. Worldwide the
international INR value should range between 2.0 and
3.0 for patients with AF [3, 4]. To avoid undercoagulation
in particular, the Dutch anticoagulation clinics use slightly
higher therapeutic target ranges of the INR, namely
between 2.5 and 3.5.
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DOI 10.1007/s12471-011-0208-zNot all patients selected for ECV receive their
treatment at the first planned hospital admission due to
a variety of reasons. The incidence and reasons for
postponing ECV procedures are still not thoroughly
studied. The aim of our study was therefore to evaluate
the waiting list for elective ECV for patients with
persistent AF in the Department of Cardiology of the
University Medical Centre Groningen, the Netherlands
(UMCG), focusing on how often and for what reason
procedures were postponed. Furthermore, we compared
the effects of the management of the waiting list
conducted by physicians versus management by nurse
practitioners (NPs). Finally we evaluated the safety of
our anticoagulation therapy and policy by means of
bleeding or thromboembolic complications during and
after ECV.
Fig. 1 Protocol for electrical
cardioversion at the University
Medical Centre Groningen
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Patients
This was a prospective observational study performed in the
UMCG between August 2008 and December 2009. We
evaluated 250 consecutive patients with persistent AF
admitted to our clinic for elective ECV. The choice for a
rhythm-control strategy was made by a dedicated AF
cardiologist and cardiologist in training, based upon medical
history, AF-associated symptoms, current medication and
echocardiographic parameters, after identifying and treating
underlying diseases which may play a role in onset and
maintenance of AF. The INR status was monitored in the
periodbeforeECVbythephysicianorNP.Ifthepatient’sIN R
dropped below the therapeutic target range during the period
between acceptance for ECVand performing ECV, the ECV
was postponed or a transoesophageal echocardiography
(TEE) was performed to exclude thrombus in the left atrium
or left atrial appendage [5]. Additionally, if the INR was
below the target range or above 5.5 on the day of admission,
the ECV was cancelled and a new appointment was made for
the patient. According to our hospital protocol, a minimum
continuous period of 4 weeks of adequate anticoagulation
was required.
The relevant medical management from acceptation until
discharge after ECV was performed by the physician until
15 June 2009. After this date, the tasks shifted. The
physician became responsible for selection of patients for
ECV, initial contact with the anticoagulation clinic and the
initial planning on the waiting list, while the NP at the short
stay unit was made responsible for maintaining contact with
the anticoagulation clinic and the necessary mutations on
the waiting list. The NP also started performing the ECV.
Electrical cardioversion
ECV was performed under short general anaesthesia provided
by a consulting anaesthesiologist [6]. Anaesthesia was
induced with propofol (typically 0.5–1 mg/kg) until loss of
consciousness. Additional bolus doses of propofol were
administered for maintenance of anaesthesia during the
procedure. Monitoring consisted of non-invasive blood
pressure measurement and pulse oxymetry.
The ECV was performed according to a standardised
protocol as has been described earlier (Fig. 1)[ 7]. In case of
immediate recurrence of AF, 750 mg magnesium was given
to increase the likelihood of successful cardioversion and to
maintain sinus rhythm afterwards [8]. A brief observation
period after ECV to assess complete recovery was provided
by the anaesthesia team. Patients were usually discharged
from the hospital 2–4 h after ECV if they were well awake
and in the absence of complications. In case of initiation of
class I or III antiarrhythmic drugs, hospitalisation was
prolonged for a period of 24–48 h.
Endpoints and follow-up
Primary endpoints of this study were time from acceptance
for ECV to date of the procedure, and reasons for
postponing the procedure, compared between management
by physician or NP. The secondary endpoints were bleeding
or thromboembolic complications. Follow-up was per-
formed after the first outpatient clinic visit by reviewing
patient medical records.
Statistical analysis
All data were analysed using SPSS version 16.0 (SPSS,
Illinois USA). Statistics are presented as mean ± standard
deviation (SD) or median (interquartile range Q25-Q75) for
continuous variables, or as numbers with percentages for
categorical variables.
We used the Mann–Whitney and χ
2 tests to analyse the
results. A double-sided p value of 0.05 or less was
considered statistically significant.
Table 1 Baseline characteristics
Characteristic All patients (n=242)
Age (years) 63±11
Male sex 173 (71.5)
BMI (kg/m
2)2 7 ± 4
Current AF duration (months) 3 (1–15)
Previous electrical cardioversion 2 (1–3)
Hypertension 126 (52.1)
Coronary artery disease 55 (22.7)
Valvular heart disease 14 (5.8)
COPD 6 (2.5)
Diabetes 23 (9.5)
History of heart failure 53 (21.9)
CHA2DS2 VASc score 2 (1–3)
NYHA class
I 130 (53.7)
II 101 (41.7)
III 11 (4.5)
Previous AAD use
Class Ic 10 (4.1)
Class III 74 (30.6)
Data are expressed as number (%) or mean±SD or median
(interquartile range)
AAD antiarrhythmic drug; BMI body mass index; COPD chronic
obstructive pulmonary disease; NYMA New York Heart Association
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First planned ECV
Of the 250 patients referred for electrical cardioversion,
8 patients (3%) were primarily not accepted for an ECV
because of an inappropriate treatment of underlying
diseases. Table 1 shows baseline characteristics of the 242
patients who underwent ECV. Most were male (72%) with
a mean age of 63 years. Duration of the current AF episode
was a median of 3 months. Figure 2 shows the flowchart of
patients who were scheduled for ECV. Within 5 to 6 weeks,
186 of 242 patients (77%) received ECV. After 5
rescheduled ECVs, all patients on the waiting list had been
treated with ECV (n=218, 90%). Patients were taken off
the waiting list for reasons of spontaneous conversion to
sinus rhythm (n=16, 7%), switch to rate control (n=5, 2%),
hospital admission for symptomatic AF necessitating an
Fig. 2 Patient flow chart over
planned and rescheduled ECV
procedures
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cardia (n=1, 1%), and crossover to pulmonary vein
ablation (n=1, 1%).
The initially planned ECV was postponed in 99 (41%)
patients (Table 2). Reasons to postpone the ECV before
admission (n=65) were inadequate INR, patients’ personal
circumstances, switch to rate control, spontaneous conver-
sion to sinus rhythm and unplanned hospital admission.
Reasons to postpone the ECV on admission (n=34) were
INR under the therapeutic range (n=11, mean INR 1.9±0.2),
INR above the therapeutic range (n=8, mean INR 7.2±1.2),
sinus rhythm at presentation, and other reasons, such as
hyperkalaemia or bradycardia. Seven patients underwent
TEE before ECV; two procedures were postponed because of
the presence of a thrombus in the left atrial appendage.
Figure 3 displays the percentages of patients whose
procedure was postponed at the first planned and each
consecutive rescheduled ECV, before and on admission.
First rescheduled ECV
Eighty-six patients (36%) were planned for a first resched-
uled ECV, which was postponed again in 43 patients (50%).
Reasons to postpone before admission (n=28) were
inadequate INR, patients’ personal circumstances and
unscheduled hospital admission. Reasons to postpone on
admission day (n=15) were INR under the therapeutic
range (n=5, mean INR 1.8±0.5), INR above the therapeutic
range (n=1, INR=7.0), sinus rhythm, and other reasons
such as bradycardia and poor adherence to the medical
regimen. Four patients underwent TEE before ECV; in
three patients this was postponed because of thrombus in
the left atrial appendage.
Second and further rescheduled ECVs
Thirty-seven patients (15%) were planned for a second
rescheduled ECV. This was postponed for the second time in
14 patients (38%). Reasons to postpone ECV before admis-
sion (n=11) were inadequate INR, spontaneous sinus rhythm
and haematuria. Reasons to postpone the ECVon admission
(n=3) were signs of heart failure and sinus rhythm.
Eleven patients (5%) were planned for a third rescheduled
ECV.In6patients(55%)thiswaspostponedforthethirdtime.
Table 2 Logistic parameters for electrical cardioversion
Postponed before
admission
Postponed on
admission
First planned ECV 65 (27) 34 (14)
n=242
Rescheduled I 28 (33) 15 (17)
n=86
Rescheduled II 11 (30) 3 (8)
n=37
Rescheduled III 5 (45) 1 (9)
n=11
Rescheduled IV 2 (40) 1 (20)
n=5
Rescheduled V 0 0
n=2
Data are expressed as number of eligible patients (%)
Fig. 3 Reasons for postponing
ECV
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inadequate INR, patients’ personal circumstances and spon-
taneous sinus rhythm. The reason to postpone the ECV on
admission (n=1) was an INR under the therapeutic range
(INR=2.0).
Five patients (2%) were planned for a fourth rescheduled
ECV. The procedure was postponed for the fourth time in
three patients (60%). Reasons to postpone ECV before
admission (n=2) were inadequate INR and patients’ personal
circumstances. The reason to postpone the ECV on admis-
sion (n=1) was an INR over the therapeutic range (INR=
10.0). Two patients (1%) were planned for a fifth resched-
uled ECV. Both patients underwent this ECV as planned
Physician compared with dedicated NP
Over the course of all ECVs, the majority of the repeatedly
postponed procedures were due to an inadequate INR (78%).
In total, patients were scheduled for an ECV 272 times. The
procedure was postponed in 23 of the 147 patients (16%)
managed by the research physician due to an inadequate INR
at admission versus 4 out of 98 patients (4%) managed by the
NP (p=0.005). Analysis of waiting lists showed a similar
number of cumulated waiting days before ECV between
management by physician and NP (Fig. 4).
Follow-up
With regard to bleeding or thromboembolic complications,
none of the 242 patients reported an event at the first
outpatient clinic visit.
Discussion
The present study provides valuable information about
patient and logistic parameters for planned ECVs. Our main
finding was that ultimately 90% of selected patients
received an ECV, despite some procedures being resched-
uled 5 times. The main reason to postpone a planned ECV
was an inadequate INR. In 7% of patients, spontaneous
conversion to sinus rhythm occurred. Furthermore, our
study showed that in the patient group managed by an NP,
the INR was more often adequate, leading to significantly
less postponed ECVs at admission. Finally, in our patient
group there were no bleeding or thromboembolic compli-
cations between ECV and first outpatient visit.
On the topic of anticoagulation status a number of papers
have been published. In a clinical trial, a recent study showed
that the patients included in the Netherlands were within the
therapeutic range for 70% of the time [9]. However, in our
study, which represents routine clinical care, we found a
lower percentage of adequate INR values. Veeger et al. [10]
reported a similar finding showing that in patients with AF
the INR was within the target range during 42% of the time.
When analysing the results, we did not discriminate between
patients followed by the anticoagulation clinic and self-
testing patients at home. A recent study shows that patients
who perform self-testing have a small but significantly
higher in-target INR range time than patients tested in a
clinic. This, however, does not lead to a difference in
thromboembolic or bleeding complications [11].
With the advance of dabigatran as anticoagulation medi-
cation instead of coumarin derivatives, closely following the
INR status will become obsolete when planning patients for
ECV.Dabigatranhasbeenshowntobeaseffectiveandsafeas
warfarin in patients with AF with respect to incidence of
stroke and systemic embolism, and lower or similar rates of
major haemorrhage depending on the dosage. We expect that
in the near future the number of postponed ECV procedures
will decrease since INR status will no longer play a key role
[9, 12–15]. On the other hand, no control on the intake of
dabigatran may have deleterious effects when ECV is
performed under inadequate anticoagulation in patients with
low compliance and warrants attention.
A total of 16 patients (7%) spontaneously converted to
sinus rhythm in the period between acceptance and
admission for ECV. Channer et al. reported spontaneous
conversion to SR in 21% of patients while waiting for ECV
[12]. All of these patients were treated with amiodarone
400 mg twice daily. Tieleman et al. found similar results in
patients with concomitant treatment with verapamil [16]. In
our study 7 patients used amiodarone, 3 patients had a
medication switch before ECV, 2 patients recently had an
invasive pulmonary vein ablation, and 4 patients had SR
without an identifiable cause.
Role of the NP
On our short stay unit, NPs systematically contact the
anticoagulation clinics about the INR status of planned Fig. 4 Waiting days before ECV, managed by physician and NP
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increased postponing of procedures prior to hospital admis-
sion, it may also prevent patient discomfort, since fewer
patients come to the hospital with an inadequate INR. The
number of postponed procedures after the patient was
admitted to the hospital showed a marked decrease under
NPmanagement. Itisunclear why the total amount ofwaiting
days did not decrease accordingly. Although this was not the
subject of our study, we hypothesise that physicians checked
INR less frequently due to other priorities. The feasibility and
safety of nurse-led elective ECV procedures and subsequent
chronic care programs with high guideline adherence have
been reported earlier [17, 18].
The fact that we saw no thromboembolic complications
at the first outpatient visit suggests that the approach of
ECV management used is safe, a finding that has been
reported previously [7].
Our study has some limitations. Firstly, it is a single-
centre study. Secondly, the number of patients decreased
with each step, leaving a small number of patients in the
fourth and fifth rescheduled ECV groups. This limits the
generalisibility of these specific findings.
Conclusion
The main reason to postpone an ECV before and at admission
is an inadequate INR. ECV was less often postponed on the
day of admission in patients managed by the NP. Within
6 weeks from acceptance, 77% of patients received ECV.
Sixteen patients developed sinus rhythm while waiting for
ECV. Management on basis of INR value is safe.
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